SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGeron Corp.


Previous 10 Next 10 
To: cycleupcycledown who wrote (3510)12/18/2021 5:05:11 PM
From: Aloner
   of 3542
 
So, how's that workin' out for ya?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: tktrimbath12/31/2021 8:19:33 PM
1 Recommendation   of 3542
 
My end of year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.393B was $0.495B)

Geron is a leading edge biotech focused on telomerase treatments dealing with hematological treatments. They continue to make progress to the point that some estimates of more general use are described in a few years rather than the decades it has taken so far. As with many innovative treatments aimed at a narrow portion of a broader illness, approval for one treatment can lead to a multiplying effect as it is applied to similar illnesses. First, fix one.

Geron was working on a wide variety of innovative treatments for decades. They sold off almost everything else. If successful, they may be a headline comeback story and benefit people dealing with few if any options.

I suspect investors familiar with the company and the technology over these years may be sitting and watching for significant, positive news. The company forecasts the commercial launch of imetelstat in lower risk MDS in the United States to be in 2024. Investors won't all wait until full approval, but it is hard to know when or if they will return, hence, I buy now and hold.



DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.net )

Share RecommendKeepReplyMark as Last Read


To: Aloner who wrote (3522)2/20/2022 11:32:58 PM
From: cycleupcycledown
   of 3542
 
I bailed months ago.....Back in last week, fire sale, $1.05

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown2/24/2022 10:26:41 PM
   of 3542
 
Dumb luck, caught bottom?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: cycleupcycledown who wrote (3525)2/26/2022 12:21:50 PM
From: tktrimbath
   of 3542
 
Skill, pure skill. Congratulations.

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown2/28/2022 12:04:18 PM
   of 3542
 
Call me tommy telomeres

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown3/18/2022 11:22:20 PM
   of 3542
 
March 10 earnings call was encouraging, positive.....Big plans in a couple of years.

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown3/30/2022 10:13:15 AM
   of 3542
 
Thought I was gonna get cut up today after dilution news, but she's up instead

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown3/30/2022 11:05:36 PM
   of 3542
 
Don't know the short situation, more fuel later............be so cool if those young whippersnappers on msg boards catch wind.

Share RecommendKeepReplyMark as Last Read


From: Savant4/4/2022 9:53:17 AM
1 Recommendation   of 3542
 
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of common stock, together with accompanying warrants to purchase 35,714,286 shares of common stock. The combined offering price to the public of each share of common stock and accompanying warrant was $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant was $1.049. The common stock and pre-funded warrants were sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $1.45 per share and expires five years from the date of issuance; however, such term will be shortened upon achievement of a regulatory milestone.

The estimated net proceeds to Geron from this underwritten public offering are approximately $70 million, after deducting the underwriting discount and other estimated offering expenses payable by Geron. Geron currently intends to use the net proceeds from this public offering, together with its existing cash, cash equivalents, restricted cash and marketable securities, to fund potential regulatory filings in the United States and European Union for imetelstat in lower risk myelodysplastic syndromes (MDS), assuming top-line results in the IMerge Phase 3 clinical trial are supportive, and to support toward the completion of the IMpactMF clinical trial in refractory myelofibrosis and the planned exploratory studies in new indications, including IMproveMF and investigator-led trials in acute myeloid leukemia and higher risk MDS, the preclinical work in lymphoid malignancies and the discovery research program related to next generation telomerase inhibitors.

Stifel and Baird acted as joint book-running managers for the public offering and Needham & Company acted as lead manager.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock, pre-funded warrants and accompanying warrants described above was previously filed with the Securities and Exchange Commission (SEC) and subsequently declared effective by the SEC. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement relating to the offering may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com or Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, Wisconsin 53202, by telephone at 800-792-2473 or by email at syndicate@rwbaird.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Use of Forward-Looking Statements

Investors are cautioned that statements in this press release regarding the anticipated net proceeds from this public offering and Geron's intended use of the net proceeds from this public offering constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: higher than estimated offering expenses; market and other conditions; and the impact of general economic, industry or political conditions in the United States or internationally, including the impact of the COVID-19 pandemic and/or the Russia/Ukraine conflict on Geron's business operations and activities. Geron will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force Geron to delay, reduce or eliminate its imetelstat development program. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on other potential factors that could affect Geron's results and other risks and uncertainties can be found under the heading "Risk Factors" in Geron's periodic reports, including its annual report on Form 10-K for the year ended December 31, 2021 and in the final prospectus supplement related to the public offering filed with the SEC on March 30, 2022, each available on the SEC's web site at www.sec.gov. Geron expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

View source version on businesswire.com: businesswire.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10